About Hikma
Hikma is a publicly listed company based in Amman (Jordan) founded in 1978. Generics and pharmaceutical products are manufactured by Hikma. It operates on a Direct-to-Consumer (D2C) and Professional Services model. The company has 9,500 employees. Hikma has completed 6 acquisitions, including Custopharm, EIMC Pharmaceuticals and Medlac Pharma. Its chief executive, as recorded, is Riad Mishlawi. Its website hikma.com draws about 159 thousand monthly visits. Hikma offers products and services including Injectables, Denosumab Biosimilars, and Morphine Sulfate Injection. Its focus areas include Pharmaceuticals and Generic and Specialty Drugs. Its legal entity in India is Hikma Pharmaceuticals PLC (U74999MH2022FTC395622).
Company details
Hikma Pharmaceuticals PLC is engaged in the development, manufacturing, and distribution of high-quality medicines across North America, MENA, and Europe. Operations are focused on generics, specialty pharmaceuticals, and injectables. Solutions are provided through strategic acquisitions, expanded manufacturing capabilities, and investment in research and development. The company is committed to sustainability and advancing health by ensuring access to medicines, maintaining product quality, and upholding ethical standards. Various therapeutic areas are addressed to improve patient outcomes worldwide.
- Indian entity net loss-₹6.4 Lakh
FY 2023 · 0% margin
- Indian entity EBITDA-₹7.8 Lakh
FY 2023 · 0% margin
- Employee Count9,500
- Investments & AcquisitionsCustopharm
& 5 more
Associated legal entities of Hikma
Hikma is associated with 2 registered companies on The Company Check; the primary company is Hikma Services India Private Limited. Each company page carries the filings, financials, charges and directors of that entity.
| Legal entity | Status | Incorporated | Registered in | Revenue (FY 2023) | Employees | Directors | Company page |
|---|---|---|---|---|---|---|---|
| Hikma Services India Private Limited CIN U62099MH2022FTC395622 | Active | 20 Dec 2022 | Mumbai, Maharashtra | 19 | 2 | View details | |
| Hikma Pharmaceuticals Plc CIN U74999MH2022FTC395622 | 20 Dec 2022 | Mumbai, Maharashtra, India | View details |
Products & Services of Hikma
Hikma offers a comprehensive portfolio of products and services, including Injectables, Denosumab Biosimilars, and Morphine Sulfate Injection.
High-quality injectable medicines are produced for global markets.
Biosimilar products are developed for bone health treatment.
Pain management injection is offered in prefilled syringes.
Apps and channels of Hikma
its YouTube channel Hikma Pharmaceuticals has 12.8K subscribers and 30 videos.
Videos from Hikma
The most watched videos on Hikma's YouTube channel, Hikma Pharmaceuticals (12.8K subscribers). Click a video to play it here.
More on Hikma Pharmaceuticals.
Board of directors of Hikma Services India Private Limited (Hikma)
Hikma Services India Private Limited is the primary company behind Hikma. The board of Hikma Services India Private Limited currently have 2 directors; the longest-serving is Francois Paul Andre Rousselot, appointed in 2022.
| Director | Designation | Appointed | Tenure | Entity |
|---|---|---|---|---|
| Francois Paul Andre Rousselot DIN 09829941 | Director | 20 Dec 2022 | 3 yrs 10 mo | Hikma Services India Private Limited |
| Mohammed Khaja Ateeq Ahmed DIN 09829942 | Director | 20 Dec 2022 | 3 yrs 10 mo | Hikma Services India Private Limited |
People of Hikma
217 people are tracked at Hikma (84 in leadership, 10 in board & advisors, 123 in team); the tracked headcount is 9,500.
| Name | Role | Group |
|---|---|---|
Riad Mishlawi | CEO | Leadership |
Shadi Khalil | Director, IT SAP Finance & Reporting At Hikma Pharmaceuticals | Leadership |
Mike Armstrong | Country Director | Leadership |
Christine Schneider | General Manager / Geschäftsführer | Leadership |
Dima Oscar | General Manager | Leadership |
Tamer Jardaneh | Vice President Egypt & Sudan | Leadership |
Matthew Burger | Director, Solids Manufacturing And MES At Hikma Pharmaceuticals | Leadership |
Stephanie Haas Ryan | Sr. Director, US Generics Procurement | Leadership |
Nathanael Craig | Director | Leadership |
Anas Alqawasmi mac | Associate Director, Coe Operations I Finance Transformation I Process Improvements | Leadership |
Adeeb Wahbeh | Penicillin Plant Associate Director | Leadership |
Michael Alianiello | Sr. Director Of Operations | Leadership |
Samuel Camocho | Associate Director - Operations | Leadership |
Abdallah abu-Asad | Director, Global IT Infrastructure & IT Business Partner | Leadership |
Maher Jadallah | Finance Director - MENA | Leadership |
Trish Bousfield | Chief Information Officer | Leadership |
Mahmoud Shanaah | Associate Director Of Operations | Leadership |
Mazen Darwazah | Executive Vice Chairman, President of MENA | Leadership |
Haifa al Basha | HR Associate Director | Leadership |
Malika Adli | Plant Director | Leadership |
197 more people are available in the full profile.
Complete people profiles for Hikma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Hikma
Hikma is a publicly listed company on the LSE with ticker symbol HIK in UK, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date04 Nov 2005
- Listed onLSE: HIK
- Listed entityHikma Pharmaceuticals Plc
- Exchange sectorHealth technology
- ISINGB00B0LCW083
- Share price1,607.00 GBX (+1.32% on the day) · 2026-10-14
- Market capitalisation3,282,513,898.00 GBX
- Price to earnings12.2
- EPS (diluted, trailing year)1.31 GBX
- Dividend yield4.04%
- Volume (last session)284,190
Financials of Hikma
Figures of Hikma Services India Private Limited, the primary company behind Hikma, for FY 2023. Net loss was -₹6.4 Lakh (0% margin). EBITDA was -₹7.8 Lakh (0% margin).
- -₹6.4 LakhNet loss · 0% margin
- -₹7.8 LakhEBITDA · 0% margin
- ₹1 LakhPaid-up capital
- 19Employees (provident fund records)
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 2.54B GBP | 305.0M GBP | 591.9M GBP |
| 2024 | 2.45B GBP | 280.9M GBP | 629.2M GBP |
| 2023 | 2.31B GBP | 152.8M GBP | 548.6M GBP |
| 2022 | 2.04B GBP | 152.6M GBP | 565.0M GBP |
| 2021 | 1.86B GBP | 306.1M GBP | 555.5M GBP |
Balance sheet, profit and loss, cash flow and ratios of Hikma Services India Private Limited are on its company page.
Detailed financial statements for Hikma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Hikma
Hikma has strategically engaged in corporate development activities, having acquired 6 companies. Notable acquisitions include Custopharm, EIMC Pharmaceuticals and Medlac Pharma.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Employee benefits administration and insurance products are provided. | custopharm.com | Carlsbad, United States | 2005 | Sep 2021 | $425M | |
Developer and manufacturer of pharmaceutical parental products | medlacpharma.com | Hanoi, Vietnam | 2008 | Nov 2018 | •••• | |
Manufacturer of oncology drugs | eimc.com.eg | Kafr Nasr Allah, Egypt | 2003 | Sep 2015 | $38M | |
Manufacturer of generics products | roxane.com | Columbus, United States | 1885 | Jul 2015 | $2.64B | |
Manufacturing of dietary supplements is conducted by Promopharm Lebanon. | promopharm-lb.com | Lebanon | 1993 | Oct 2011 | $153M | |
Pharmaceutical, dermo-pharmaceutical, and cosmetology products are manufactured and distributed. | promopharm.co.ma | Casablanca, Morocco | 1985 | Oct 2011 | $153M |
Complete acquisition details for Hikma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Hikma
8 dated milestones of Hikma across 43 years, from founding to its latest funding, stage changes and deals.
- Founded Hikma is founded.
- IPO Lists on the stock exchange (IPO).
- Acquisition Acquires Promopharm.
- Acquisition Acquires Promopharm Lebanon.
- Acquisition Acquires Roxane Laboratories.
- Acquisition Acquires EIMC Pharmaceuticals.
- Acquisition Acquires Medlac Pharma.
- Acquisition Acquires Custopharm.
Web traffic of Hikma
The website of Hikma (hikma.com) receives about 159K visits a month and ranks #227,704 among all websites worldwide, #7,536 in Biotechnology and Pharmaceuticals.
- Monthly visits159K
▼ 10.4% vs previous month
- Unique visitors68K
per month
- Global rank#227,704
among all websites
- Category rank#7,536
Health · Biotechnology and Pharmaceuticals
- Bounce rate39%
- Pages per visit2.9
- Average visit2 min 35 sec
- DevicesDesktop 33% · Mobile 67%
Websites whose visitors overlap most with Hikma. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| dadgroup.com | 100% | 680.7K | #3,450,381 | View details | |
| tevapharm.com | 86% | 166.9K | #278,209 | View details | |
| parpharm.com | 82% | View details | |||
| ribosepharm.de | 76% | View details | |||
| fareva.com | 74% | 14.6K | #1,040,773 | View details | |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
| •••••••••• | ••••••.com | ••% | •.•M | #••••• | – |
All 40 similar websites and full traffic analytics for Hikma
The complete similar-websites list, audience overlap and engagement analytics require an active premium plan.
- 40 similar websites
- Audience overlap
- Engagement analytics
- Traffic by brand
Verified entity values are shown only after access is granted.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Hikma
Complete news archive for Hikma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Hikma
Hikma was founded in 1978.
Hikma is headquartered in Amman, Jordan.
Riad Mishlawi is the CEO of Hikma, as recorded in our data.
Hikma has 9,500 employees.
Annual revenue of Hikma is $3.42B as on Dec 31, 2025.
Hikma Pharmaceuticals PLC is engaged in the development, manufacturing, and distribution of high-quality medicines across North America, MENA, and Europe. Operations are focused on generics, specialty pharmaceuticals, and injectables. Solutions are provided through strategic acquisitions, expanded manufacturing capabilities, and investment in research and development. The company is committed to sustainability and advancing health by ensuring access to medicines, maintaining product quality, and upholding ethical standards. Various therapeutic areas are addressed to improve patient outcomes worldwide.
Hikma offers Injectables, Denosumab Biosimilars, and Morphine Sulfate Injection.
Yes, Hikma is publicly traded on LSE under the ticker symbol HIK.
Hikma has made 6 acquisitions, including Custopharm, EIMC Pharmaceuticals, and Medlac Pharma.
Hikma operates through Hikma Services India Private Limited.
The legal entities of Hikma currently have 2 directors, including Francois Paul Andre Rousselot, Mohammed Khaja Ateeq Ahmed.
The website of Hikma receives about 159 thousand visits a month and ranks #227,704 among all websites worldwide.